Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida, May 29 through June 2, 2009.
 

The presentation for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows:
 

 Time: Saturday, May 30, 2009: 8:00 a.m. - 12:00 p.m. EDT Poster Phase I evaluation of SF1126 a vascular targeted PI3K Title: inhibitor administered twice weekly IV in patients with refractory solid tumors Presenter: Elena G. Chiorean, MD Location: Level 2 - West Hall C. Poster Session Track: #79 Developmental Therapeutics: Cytotoxic Chemotherapy; Poster Board B19 (Abstract # 2558) About SF1126 

SF1126 is the only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment.
 

In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway.
 

About PI3 Kinase
 

Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mTOR is also known to promote tumor cell survival, proliferation, and growth. Notably, dysregulation of PI3K signaling is thought to contribute to resistance to a variety of anticancer therapies. Thus, PI3K is considered a high value target in treating cancer.
 

About Semafore Pharmaceuticals, Inc.
 

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN inhibitors. The Company has successfully discovered and is developing a portfolio of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information see the company's web site at www.SemaforePharma.com.
 

Source: Semafore Pharmaceuticals, Inc.

CONTACT: Sandi Yurichuk of Semafore Pharmaceuticals, Inc.,
+1-650-576-5769, sandi.yurichuk@semaforepharma.com
 

Web Site: http://www.semaforepharma.com/
 

Posted: May 2009

View comments

Hide
(web4)